$hims
Altimmune weight loss drug gets fast track greenlight; Hims poised to enter GLP1 race with strategic edge
Altimmune and Hims are both playing in one of the most explosive medical markets of this decade. The weight loss drug arms race has gone full tilt, and while Novo Nordisk and Eli Lilly have soaked up the spotlight with … Read more
Oscar Health hits $10B. Hims & Hers on track for $2.4B in 2025. Both firms now building full-stack health platforms.
Revenue growth like this doesn’t come from noise. It happens when a company locks in product fit and turns it into system-wide expansion. Two firms are now flashing numbers that match the kind of vertical control tech investors chase. Oscar … Read more